DK0567566T4 - Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme - Google Patents

Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme

Info

Publication number
DK0567566T4
DK0567566T4 DK92904429T DK92904429T DK0567566T4 DK 0567566 T4 DK0567566 T4 DK 0567566T4 DK 92904429 T DK92904429 T DK 92904429T DK 92904429 T DK92904429 T DK 92904429T DK 0567566 T4 DK0567566 T4 DK 0567566T4
Authority
DK
Denmark
Prior art keywords
tnf inhibitor
methods
40kda
mediated diseases
treatment
Prior art date
Application number
DK92904429T
Other languages
English (en)
Other versions
DK0567566T3 (da
Inventor
Robert C Thompson
David F Carmichael
Christopher G Smith
Deborah Russell
Tadahiko Kohno
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24584497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0567566(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DK0567566T3 publication Critical patent/DK0567566T3/da
Application granted granted Critical
Publication of DK0567566T4 publication Critical patent/DK0567566T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK92904429T 1991-01-18 1992-01-17 Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme DK0567566T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64434591A 1991-01-18 1991-01-18
PCT/US1992/000432 WO1992013095A1 (en) 1991-01-18 1992-01-17 Methods for treating tumor necrosis factor mediated diseases

Publications (2)

Publication Number Publication Date
DK0567566T3 DK0567566T3 (da) 2000-07-31
DK0567566T4 true DK0567566T4 (da) 2007-10-22

Family

ID=24584497

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92904429T DK0567566T4 (da) 1991-01-18 1992-01-17 Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme

Country Status (15)

Country Link
EP (1) EP0567566B2 (da)
JP (2) JP2864434B2 (da)
KR (1) KR100234520B1 (da)
AT (1) ATE190629T1 (da)
AU (2) AU1235692A (da)
CA (1) CA2100329C (da)
DE (1) DE69230789T3 (da)
DK (1) DK0567566T4 (da)
ES (1) ES2145744T5 (da)
GE (1) GEP20002142B (da)
GR (1) GR3033327T3 (da)
NO (1) NO316310B1 (da)
RU (1) RU2166955C2 (da)
SG (1) SG63617A1 (da)
WO (1) WO1992013095A1 (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0611302B1 (en) * 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
DE69327582T2 (de) * 1992-04-30 2000-08-03 Amgen Inc., Thousand Oaks Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
JPH07504203A (ja) * 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU715260B2 (en) 1995-07-14 2000-01-20 Laboratoires Serono Sa TNF receptor and steroid hormone in a combined therapy
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
WO1999023879A1 (en) * 1997-11-07 1999-05-20 Uab Research Foundation Method for the augmentation of gene expression
WO2000023471A2 (en) * 1998-10-20 2000-04-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2401683A1 (en) 2000-03-02 2001-09-07 Xencor Design and discovery of protein based tnf-.alpha. variants for the treatment of tnf-.alpha. related disorders
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
ES2907826T3 (es) 2001-06-26 2022-04-26 Amgen Inc Anticuerpos para OPGL
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
RS89204A (en) 2002-04-10 2006-12-15 Applied Research Systems Ars Holding N.V. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
KR101015682B1 (ko) 2002-10-08 2011-02-22 아레스 트레이딩 에스.에이. Ｉｌ-18ｂｐ에 결합할 수 있고 제 2 사이토킨의 활성을저해할 수 있는 사이토킨의 용도
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
WO2006114387A2 (en) 2005-04-26 2006-11-02 Laboratoires Serono S.A. Insp163 polypeptides for the treatment or prevention of cancer and arthritis
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
CA2610804C (en) 2005-06-10 2013-11-19 Ares Trading S.A. Process for the purification of il-18 binding protein
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
EP2390263A1 (en) 2005-08-26 2011-11-30 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
KR20080050591A (ko) 2005-09-01 2008-06-09 아레스 트레이딩 에스.에이. 시신경염 치료
AU2006310577B2 (en) 2005-10-31 2012-04-19 Merck Serono Sa Use of SDF-1 for the treatment and/or prevention of neurological diseases
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
IL173104A0 (en) 2006-01-12 2006-06-11 Yeda Res & Dev Siva and ubiquintination
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP2010516744A (ja) 2007-01-26 2010-05-20 メルク セローノ ソシエテ アノニム 油体技術を用いたＦｃ−融合タンパク質の精製
JP2011500757A (ja) 2007-10-22 2011-01-06 メルク セローノ ソシエテ アノニム Ｆｃ含有タンパク質の精製方法
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
EP2899212B1 (en) 2009-03-30 2017-07-19 Edimer Biotech S.a. Preparation of isolated agonist anti-EDAR monoclonal antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011088120A1 (en) 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
US9597325B2 (en) 2010-10-13 2017-03-21 Trustees Of Boston University Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3461482A1 (en) 2012-03-16 2019-04-03 Children's Medical Center Corporation Calcium channel blockers for the treatment of ribosomal disorders and ribosomapathies
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
ES2892923T3 (es) 2013-09-05 2022-02-07 Ab2 Bio Sa Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias
JP6596014B2 (ja) 2014-03-31 2019-10-23 アムジェン ケー・エー，インコーポレイテッド 爪および頭皮乾癬の治療方法
JP7274259B2 (ja) 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
FI3484474T3 (fi) 2016-07-13 2024-07-04 Childrens Medical Ct Corp Kalmoduliinin estäjät, chk2:n estäjät ja rsk:n estäjät ribosomaalisten häiriöiden ja ribosomopatioiden hoitamiseksi
MA47362A (fr) 2017-01-30 2019-12-04 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
KR20190115042A (ko) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2021224432A1 (en) 2020-05-06 2021-11-11 Ab2 Bio Sa Il-18 binding protein (il-18bp) in respiratory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023166206A1 (en) 2022-03-04 2023-09-07 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
DK0575545T3 (da) * 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider

Also Published As

Publication number Publication date
EP0567566B1 (en) 2000-03-15
DE69230789D1 (de) 2000-04-20
CA2100329C (en) 2009-09-29
ES2145744T3 (es) 2000-07-16
NO932610D0 (no) 1993-07-19
EP0567566A1 (en) 1993-11-03
GR3033327T3 (en) 2000-09-29
JP2864434B2 (ja) 1999-03-03
JPH06506446A (ja) 1994-07-21
SG63617A1 (en) 1999-03-30
EP0567566B2 (en) 2007-07-04
DK0567566T3 (da) 2000-07-31
JPH11199505A (ja) 1999-07-27
ES2145744T5 (es) 2008-02-01
WO1992013095A1 (en) 1992-08-06
JP3210629B2 (ja) 2001-09-17
CA2100329A1 (en) 1992-07-19
GEP20002142B (en) 2000-06-25
ATE190629T1 (de) 2000-04-15
KR100234520B1 (ko) 1999-12-15
AU1235692A (en) 1992-08-27
EP0567566A4 (en) 1994-10-05
NO932610L (no) 1993-09-09
NO316310B1 (no) 2004-01-12
AU4228896A (en) 1996-04-18
DE69230789T3 (de) 2007-10-31
DE69230789T2 (de) 2000-08-31
RU2166955C2 (ru) 2001-05-20
AU702466B2 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
DK0567566T3 (da) Fremgangsmåder til behandling af tumornekrosefaktormedierede sygdomme
RU93051522A (ru) Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток
DK0639079T3 (da) Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
KR950701350A (ko) 부작용 감소와 동시에 인터페론을 이용한 질환의 치료방법 및 조성물(methods and compositions for the treatment of diseases with interferon while reducing side effects)
JP2004518632A5 (da)
DK0512528T3 (da) Farmaceutisk præparat omfattende et cytokin
DE69215722D1 (de) Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
DE69433501D1 (de) Oxazole zur behandlung von zytokinvermittelten erkrankungen
DK16890A (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
DK1854809T3 (da) Nukleinsyre og tilsvarende protein betegnet 158P1D7, der er anvendelig i behandling og påvisning af blærecancer og andre cancere
DK241287A (da) Anvendelse af glutamin til fremstilling af et laegemiddel til behandling af kataboliske forstyrrelser
DK0687184T3 (da) Rekombinante adenoviruser og anvendelse deraf ved genterapi til behandling af øjensygdomme
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
ATE341316T1 (de) Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
DK0859630T3 (da) Kombination af termozolomid og alfa-IFN til behandling af fremskreden cancer
ES2111068T3 (es) Proteina anti-vih, tap 29, a partir de trichosanthes codificada adn y usos terapeuticos de la misma.
ATE109349T1 (de) 3-substituierte-2-oxindolderivate als interleukin-biosynthesehemmer.
MX9606137A (es) Composiciones y metodos para el tratamiento de tumores.
BG101716A (en) 4,4-(DISUBSTITUTED)CYCLOHEXAN-l-OLS MONOMERS AND RELATED COMPOUNDS
EP0321094A3 (en) Treatment of factor viii inhibitors
NO20022187L (no) Fremgangsmåte for behandling og forebygging av neurodegenerative forstyrrelser
RU93037460A (ru) Способ лечения псориаза и пузырчатки
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox